8-K: Avid Bioservices Achieves Record Quarterly Revenue, Eyes Growth in Fiscal Year 2025

Avid Bioservices reports record fourth-quarter revenue of $43 million and provides a positive revenue outlook for fiscal year 2025.

Summary

• Avid Bioservices reported its financial results for the fourth quarter and fiscal year ended April 30, 2024.
• The company achieved record quarterly revenue of $43 million in Q4, an 8% increase compared to the same period last year.
• Full-year revenue for fiscal year 2024 was $139.9 million, a decrease of 6% compared to the previous year.
• The company's backlog stands at $193 million as of April 30, 2024, with a significant portion expected to be recognized as revenue over the next five fiscal quarters.
• Avid is providing revenue guidance for fiscal year 2025 between $160 million and $168 million, representing a 17% growth at the midpoint.
• The company completed a three-year expansion program, increasing its annual revenue-generating capacity from approximately $120 million in fiscal 2021 to over $400 million.
• The company recorded a net loss of $123.1 million for the fourth quarter and $140.8 million for the full fiscal year 2024, primarily due to a $118.5 million valuation allowance on deferred tax assets.
• Excluding the tax provision, the adjusted net loss was $4.6 million for the quarter and $22.3 million for the full year.
• The company expects to generate positive cash flow during fiscal year 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to record quarterly revenue and strong future guidance, but tempered by significant losses and reduced gross margins for the full fiscal year. The company's expansion and new facilities are positive, but the financial results show a mixed picture.

Positives

• The company achieved record quarterly revenue of $43 million.
• Avid has a strong backlog of $193 million, indicating future revenue potential.
• The company is projecting significant revenue growth for fiscal year 2025, with guidance between $160 million and $168 million.
• The completion of the three-year expansion program has significantly increased the company's revenue-generating capacity.
• The company expects to achieve positive cash flow in fiscal year 2025.
• The company has seen increased interest in its newly completed facilities and expanded capabilities.
• The company achieved a Committed Badge from EcoVadis for sustainability.

Negatives

• The company reported a net loss of $123.1 million for the fourth quarter and $140.8 million for the full fiscal year 2024.
• Gross profit for the full fiscal year 2024 was $7.3 million, a significant decrease compared to $31.5 million in the previous year.
• The company recorded a $118.5 million valuation allowance on deferred tax assets.
• Full-year revenue for fiscal year 2024 decreased by 6% compared to the previous year.
• Gross margin decreased to 5% for the full fiscal year 2024, compared to 21% in the previous year.

Risks

• The company may experience delays in engaging new customers.
• There is a risk that the company may not be successful in executing customer projects.
• Changing economic conditions may delay or adversely impact the realization of the company's backlog.
• The company may not be able to convert its backlog into revenue within the contemplated time periods.
• Technical difficulties in completing customer projects could result in project terminations or delays.
• Later-stage customers may not receive regulatory approval or commercial demand for approved products may be less than forecast.
• Existing customers may terminate contracts or reduce demand for services.
• Expanding into new biologics manufacturing capabilities may distract management.
• There may be delays in hiring qualified individuals for the cell and gene therapy business.
• The cell and gene therapy business may not become profitable for several years.

Future Outlook

The company anticipates significant revenue growth in fiscal year 2025, with revenue guidance between $160 million and $168 million, and expects to generate positive cash flow during the year. They also expect increased capacity utilization and margin improvements.

Management Comments

• The fourth quarter of fiscal 2024 was a high point for the company, stated Nick Green, president and CEO of Avid Bioservices.
• We generated the highest quarterly revenues in Avids history, meeting our current revenue expectations for the year.
• Given our strong backlog and robust proposal pipeline we are looking ahead to a promising 2025.
• Supporting our optimism, is the growing interest we've seen in our newly completed facilities and expanded capabilities.
• We ended the year in a position of strength with positive revenue momentum building, particularly in the second half of fiscal 2024, continued new business wins and line of sight to margin expansion.

Industry Context

The announcement reflects the growing demand for contract development and manufacturing services in the biologics sector, particularly for mammalian and cell and gene therapies. Avid's expansion and focus on later-stage programs align with industry trends towards outsourcing complex manufacturing processes.

Comparison to Industry Standards

• Avid's revenue growth guidance of 17% at the midpoint for fiscal year 2025 is a strong indicator of growth in the CDMO sector, which is generally experiencing high demand.
• Companies like Catalent and Lonza, which are major players in the CDMO space, have also been expanding their capacity to meet the increasing demand for biologics manufacturing.
• The completion of Avid's three-year expansion program, increasing its annual revenue-generating capacity to over $400 million, positions it to compete more effectively with larger CDMOs.
• The company's focus on cell and gene therapy manufacturing aligns with a rapidly growing segment of the industry, where there is a significant need for specialized manufacturing capabilities.
• While Avid's gross margin of 5% for fiscal year 2024 is lower than some industry benchmarks, the company expects margin improvements in the coming year due to increased capacity utilization.

Stakeholder Impact

• Shareholders may be concerned about the net loss for the fiscal year, but encouraged by the revenue growth guidance and future cash flow expectations.
• Employees may benefit from the company's expansion and growth, but may also be impacted by the company's financial performance.
• Customers will benefit from the company's expanded capacity and capabilities.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors will be monitoring the company's financial performance and cash flow.

Next Steps

• The company will focus on onboarding and executing new programs in its mammalian and CGT facilities.
• Avid will work to increase capacity utilization and improve margins.
• The company will continue to pursue new business opportunities and convert its backlog into revenue.
• The company will monitor and potentially adjust the deferred tax asset valuation allowance based on future performance.

Key Dates

Keywords

CDMO, biologics, contract manufacturing, revenue, backlog, cell and gene therapy, manufacturing, financial results, expansion, biotechnology